Drug Profile
Research programme: hepatitis C virus NS3 protein inhibitors - IRBM
Alternative Names: Hepatitis C virus NS3 protease inhibitors research programme - IRBMLatest Information Update: 22 Apr 2003
Price :
$50
*
At a glance
- Originator IRBM
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 08 Sep 2000 Preclinical development for Hepatitis C in Italy (Unknown route)